US EditionNine of the largest pharma companies ink deals with Trump to lower drug prices
Nine major pharmaceutical companies agreed to cut Medicaid drug prices by up to 70% and invest $150 billion in U.S. manufacturing in exchange for tariff relief, the White House said.
- On Friday, President Donald Trump announced deals with nine pharmaceutical companies to cut prices for Medicaid recipients and cash-paying consumers, listing medicines on TrumpRx for launch next year.
- The administration leaned on tariff threats and incentives, using an executive order and tariff exemptions to pressure firms into adopting a most-favored-nation pricing model.
- Among the specific discounts, Gilead's Epclusa dropped from $24,920 to $2,425, Sanofi's Plavix to $16 from $756, and Bristol Myers Squibb's Reyataz to $217 from $1,449.
- The White House says the agreements will deliver "billions of dollars in savings" while the companies pledged at least $150 billion in U.S. investment and Merck committed over $70 billion.
- TrumpRx is slated to be operational in January, officials say, while Democratic senators seek specific drug pricing details and the remaining companies expected—AbbVie, Johnson & Johnson, Regeneron—may announce deals next week.
294 Articles
294 Articles
Since his residence in Mar-a-Lago, Florida, Donald Trump reported a telephone conversation he would have had with Emmanuel Macron to convince him of an increase in the price of medicines. "Accept now please. Be kind," said the American president to his counterpart.
"Accept now please. Be kind...": Donald Trump delivered his version to him on Monday in a conversation with Emmanuel Macron, at the end of which the French president would have been forced to accept his demands on the price of medicines.Since his residence in Mar-a-Lago in Florida, the American president told an anecdote that he had already enjoyed his supporters Friday night during a meeting. "I spoke to a very good man, President Macron of Fra…
ABC FOX Montana
Trump administration announces plan to lower US drug costs
WASHINGTON, D.C. – President Donald Trump unveiled "most favored nation" pricing deals on Friday with nine pharmaceutical companies. This initiative aims to lower drug costs for Medicaid and launch new medications in the U.S. at these reduced prices.
U.S. President Donald Trump announced Friday agreements with nine other pharmaceutical companies to reduce the prices of some drugs, an action that is part of his efforts to match the cost of certain drugs with the lowest prices paid in other countries.With Friday's agreement, which includes Bristol Myers Squibb, Genentech, Boehringer Ingelheim, Sanofi, Novartis, Merck, Gilead, GSK and Amgem, 14 major pharmaceutical companies have already agreed…
Coverage Details
Bias Distribution
- 62% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
